Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N6-cyclopentyladenosine is a **selective adenosine A1 receptor agonist** used primarily as a pharmacological tool in scientific research. It displays high affinity for the adenosine A1 receptor (Ki = 2.3 nM), with much lower affinity for A2A (Ki = 790 nM) and A3 (Ki = 43 nM) receptors, and very low activity at A2B (EC50 = 18600 nM)[1][16]. Its main effects are **cardiovascular—bradycardia and hypotension—via adenosine A1 receptor activation**; it also produces behavioral and central nervous effects, such as memory impairment and modulation of seizure thresholds in animal models[3][7][12]. It is **not approved for clinical or therapeutic use**, but widely used as a reference agonist for adenosine A1 receptor function in cardiovascular, neurological, and biochemical studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n6-cyclopentyladenosine.